ReviewTherapeutic advances in vaccines and immunotherapy2018
Bispecific antibodies in cancer immunotherapy.
Review in Therapeutic advances in vaccines and immunotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 1 synthesis or guideline pooled it, 200 citations in OpenAlex.
- The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies.Frontiers in pharmacology · 2026Pooled it
- Article
- Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses.Molecular therapy. Oncology · 2026Article
- Immunotherapy Landscape of Advanced Clear Cell Renal Cell Carcinoma: Targeting the Cancer-Immunity Cycle and Future Perspectives.Biomedicines · 2026Review
- Aligning preclinical AML models with immunotherapy development: principles for model selection.Frontiers in immunology · 2026Review
- A novel immunocytokine promotes T cell- and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma.Journal of translational medicine · 2025Article
- Targeting Claudin18.2 for cancer theranostics: From molecular imaging to precision therapy.iScience · 2025Review
- Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Review
- Assessing the causal association between 731 immunophenotypes and the risk of colorectal cancer: a Mendelian randomization study.BMC cancer · 2025Article
- Advances in cancer immunotherapy and future directions in personalized medicine.Open life sciences · 2025Review
- Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology.Anti-cancer agents in medicinal chemistry · 2025Review
- Mechanistic insights into resistance mechanisms to T cell engagers.Frontiers in immunology · 2025Review
- Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.International journal of biological sciences · 2025Review
- Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.Molecular cancer therapeutics · 2024Article
- Article
- Identifying biomarkers for treatment of uveal melanoma by T cell engager using a QSP model.NPJ systems biology and applications · 2024Article
- Radiolabelling and preclinical characterisation of [European journal of nuclear medicine and molecular imaging · 2024Article
- Siglec15/TGF-β bispecific antibody mediates synergistic anti-tumor response against 4T1 triple negative breast cancer in mice.Bioengineering & translational medicine · 2024Article
- mRNA vaccine development and applications: A special focus on tumors (Review).International journal of oncology · 2024Review
- Facile Access to Branched Multispecific Proteins.Bioconjugate chemistry · 2024Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeutic bispecific antibodies: (a) cytotoxic effector cell redirectors; (b) tumor-targeted immunomodulators; and (c) dual immunomodulators. Cytotoxic effector cell redirectors are dominated by T-cell redirecting compounds, bispecific compounds engaging a tumor-associated antigen and the T-cell receptor/CD3 complex, thereby redirecting T-cell cytotoxicity to malignant cells. This is the most established class of bispecific immunotherapies, with two compounds having reached the market and numerous compounds in clinical development. Tumor-targeted immunomodulators are bispecific compounds binding to a tumor-associated antigen and an immunomodulating receptor, such as CD40 or 4-1BB. Such compounds are usually designed to be inactive until binding the tumor antigen, thereby localizing immune stimulation to the tumor environment, while minimizing immune activation elsewhere. This is expected to induce powerful activation of tumor-specific T cells with reduced risk of immune-related adverse events. Finally, dual immunomodulators are bispecific compounds that bind two distinct immunomodulating targets, often combining targeting of PD-1 or PD-L1 with that of LAG-3 or TIM-3. The rationale is to induce superior tumor immunity compared to monospecific antibodies to the same targets. In this review, we describe each of these classes of bispecific antibodies, and present examples of compounds in development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.